Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Fineline Cube Sep 9, 2026
Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Policy / Regulatory R&D

CDE Issues Guidelines on Single-Arm Clinical Trials for Antitumor Drugs

Fineline Cube Mar 15, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for the Applicability of...

Company Deals R&D

XtalPi and DP Technology Partner to Accelerate Pre-Clinical Drug Development with AI

Fineline Cube Mar 15, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a partnership with Beijing-based DP...

Company Deals

Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies

Fineline Cube Mar 15, 2023

China’s Laekna Therapeutics Shanghai Co., Ltd has filed for an initial public offering (IPO) with...

Company Drug

LanssonPharm’s Anti-Depression Drug LS21031 Receives CDE Approval for Clinical Trials

Fineline Cube Mar 14, 2023

China-based central nervous system (CNS) drug developer LanssonPharm has announced that it has received clinical...

Company Drug

GSK’s Nucala Gains NMPA Approval for Severe Eosinophilic Asthma in China

Fineline Cube Mar 14, 2023

UK-based GSK plc (NYSE: GSK) has announced that a market approval filing for Nucala (mepolizumab)...

Company Drug

Juventas Cell Therapy’s CNCT19 Receives FDA IND Approval for r/r B-ALL Treatment

Fineline Cube Mar 14, 2023

China-based Juventas Cell Therapy Ltd’s chimeric antigen receptor (CAR) T-cell therapy, CNCT19 (Inaticabtagene Autoleucel), has...

Company Drug

Bio-Thera Solutions Initiates First Patient Dosing in Phase I Study of BAT8007

Fineline Cube Mar 14, 2023

China-based Bio-Thera Solutions, Ltd. (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Antengene to Begin Phase I Clinical Study of ATG-022 for Advanced Solid Tumors

Fineline Cube Mar 14, 2023

China-based Antengene Corporation Ltd (HKG: 6996) is poised to commence a Phase I clinical study...

Company Drug

Guangdong Zhongsheng’s RAY1225 Receives NMPA Approval for Clinical Study

Fineline Cube Mar 14, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received approval...

Company Deals

AnnJi Pharma Signs USD 250 Million Licensing Deal with Avenue Therapeutics for Kennedy’s Disease Drug

Fineline Cube Mar 14, 2023

Taiwan-based AnnJi Pharmaceutical Co., Ltd has announced the signing of a licensing agreement with US...

Company Drug

Vcanbio’s VUM02 Gains CDE Review for Liver Failure and ARDS Clinical Trials

Fineline Cube Mar 14, 2023

Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that two additional clinical...

Company Drug

Luye Pharma’s Biosimilar BA9101 Completes Phase III Study Enrollment with Ocumension

Fineline Cube Mar 14, 2023

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has completed...

Company Deals

Immunophage Biotech Raises RMB 200 Million in Series B1 Financing for Clinical Trials

Fineline Cube Mar 14, 2023

Nanjing-based Immunophage Biotech Co., Ltd reportedly raised close to RMB 200 million (USD 29.1 million)...

Company Drug

Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer

Fineline Cube Mar 14, 2023

China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...

Company Drug

CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing

Fineline Cube Mar 14, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...

Deals R&D

Pasteur Institute Suspends Joint Venture with Chinese Academy of Sciences

Fineline Cube Mar 14, 2023

France’s Pasteur Institute has announced its decision to suspend its joint-venture (JV) partnership with the...

Company Medical Device

Boston Scientific Launches REPLACE Study for FARAPULSE PFA System in China

Fineline Cube Mar 14, 2023

US-based medical technology major Boston Scientific Corporation (NYSE: BSX) has announced the initiation of the...

Company Drug

Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan

Fineline Cube Mar 13, 2023

Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...

Company Deals

Silicon Valley Bank Collapse Impacts Tech and Biotech Sectors Globally

Fineline Cube Mar 13, 2023

The tech and biotech sectors are grappling with the implications of the collapse of US-based...

Company Deals

Allorion Therapeutics Raises USD 50 Million in Series B Financing to Advance Drug Development

Fineline Cube Mar 13, 2023

Allorion Therapeutics, a next-generation precision medicine small molecule drug developer based in Guangzhou, reportedly raised...

Posts pagination

1 … 603 604 605 … 718

Recent updates

  • CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops
  • Gilead Opens Foster City Research Center for Oncology and Inflammation
  • Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data
  • China Launches Five-Year Plan to Expand High-Quality Eye Health Services
  • Ascletis Starts US Phase 1 Trial of Oral ASC36 for Obesity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Company Drug

Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data

Policy / Regulatory

China Launches Five-Year Plan to Expand High-Quality Eye Health Services

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.